THE FIRST-IN-CLASS BIOMIMETIC TAVRVALVE SHAPED FOR NATIVE PERFORMANCE
LIVE IN THE CATH LAB
Watch Anteris Technologies CEO, Wayne Paterson, connect live to the Cath Lab in Tbilisi, Georgia for an update on the DurAVR™ THV First In Human study with implanting physicians.
PCR-LV 2023 DURAVR™ THV EFS & FIH DATA PRESENTATION
See the Early Feasibility Study (EFS) data presented at PCR London Valves 2023, showing excellent sustained haemodynamic performance at 30 days post-implantation.
See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.
Watch this physician panel and hear Drs Michael Reardon, Rebecca Hahn, Christopher Meduri, and Azeem Latib discuss the design of the DurAVR™ THV and its impact on haemodynamics.
TCT 2023 DURAVR™ THV EFS DATA PRESENTATION
See the Early Feasibility Study (EFS) discharge data presented at TCT 2023, showing remarkable haemodynamic performance.
See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.
See the latest First-in-Human (FIH) Study data presented at TCT 2023, showing sustained mean haemodynamic performance from all 20 patients at 6 months post-procedure.
See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.
See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.
See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.
Watch this physician panel and hear Drs Christopher Meduri, Susheel Kodali, and João Cavalcante discuss early safety and feasibility of the first-in-class biomimetic transcatheter aortic valve – DurAVR™ THV.
LIVE PHYSICIAN INTERVIEW AT AGM
CEO Wayne Paterson and Dr. Karl Poon discuss his experience with DurAVR™ at Anteris Technologies’ Annual General Meeting.
POWERED BY SCIENCE. DEVELOPED BY EXPERTS.
Shaped for native haemodynamic performance for patients with severe aortic stenosis, DurAVR™ Transcatheter Heart Valve elevates science.
Anteris Technologies is a Structural Heart Company committed to discovering, developing, and delivering a pipeline of innovative medical device solutions that aim to improve the health outcomes of patient populations and dramatically improve people's lives.
INVEST IN ANTERIS (ASX: AVR)
We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.
We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.